Management's discussion and analysis of financial condition and results of operations references strategic growth investments, which generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects, and other expenditures to enhance the customer experience. The company continues to execute its proven growth strategy, which consists of developing high-impact, innovative new products, leveraging scale in high-growth and emerging markets, and delivering a unique value proposition to customers. The company's references to productivity improvements generally refer to improved cost efficiencies from its practical process improvement business system, including reduced costs resulting from implementing continuous improvement methodologies and global sourcing initiatives. The company has made notable acquisitions that expand its capabilities, such as the acquisition of the European viral vector manufacturing business, which provides manufacturing services for vaccines and therapies, and the acquisition of Mesa Biotech, which enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics. The company's operational flexibility is demonstrated through its ability to scale and evolve its molecular diagnostics solutions and plastic consumables businesses in response to the ongoing COVID-19 pandemic. The company has also expanded its capacity to meet the needs of pharma and biotech customers as they have expanded their own production volumes to meet global vaccine manufacturing requirements. The company's investments in technology resources and capabilities are expected to enhance its competitive advantage and support business transformation. The integration of acquired businesses has been aimed at enhancing operational efficiency and improving customer relationships, thereby contributing to the overall firm performance. The company’s strategic resource allocation reflects its commitment to leveraging technology functionalities and capabilities to drive innovation and improve market-based performance. The company evaluates segment operating performance using operating income before certain charges/credits, indicating a focus on operational effectiveness and strategic management practices. The company’s financial activities, including cash flows from operations and investments in working capital, support its ability to mobilize resources effectively and respond to market dynamics. The company’s ability to provide data and information to users with appropriate levels of accuracy, timeliness, reliability, security, and access is critical to its information management capability. The firm’s IT capabilities have evolved to encompass the coordination of assets and internal processes, enhancing its ability to manage interfirm transactions and relationships. The company remains well positioned to meet customer needs by leveraging its technology infrastructure and capabilities to drive business process optimization and performance improvement. The firm’s strategic alignment with market demands and consumer choice further underscores its commitment to maintaining operational agility and responsiveness in a competitive environment.